HCW Biologics Inc. (NASDAQ:HCWB) CFO Purchases $220,012.00 in Stock

HCW Biologics Inc. (NASDAQ:HCWB) CFO Rebecca Byam purchased 8,462 shares of the business’s stock in a transaction on Thursday, May 8th. The stock was purchased at an average cost of $26.00 per share, for a total transaction of $220,012.00. Following the completion of the acquisition, the chief financial officer now directly owns 43,010 shares of the company’s stock, valued at approximately $1,118,260. The trade was a 24.49% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

HCW Biologics Trading Down 20.0%

Shares of HCWB opened at $5.72 on Monday. HCW Biologics Inc. has a 12 month low of $5.22 and a 12 month high of $100.80. The stock has a fifty day moving average price of $10.01 and a 200-day moving average price of $14.75. The firm has a market cap of $6.42 million, a PE ratio of -5.72 and a beta of 0.85.

HCW Biologics (NASDAQ:HCWB) last released its quarterly earnings results on Friday, March 28th. The company reported ($3.20) EPS for the quarter. HCW Biologics had a negative net margin of 1,067.82% and a negative return on equity of 2,516.84%. The business had revenue of $0.40 million during the quarter.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.